EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed, Tumor Metabolism Regulated (TMR) CAR-T Product at ASCO GI 2025
Nodose-limiting toxicities, severe adverse events ,or on-target off-tumor toxicities across all dose cohorts Deep and durable response observed in gastroesophageal cancer EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs within vivo GCARTM platform and SCL mRNA technology WEST PALM BEACH, FL – January 23, 2025 /PRNewswire/ –EXUMA Biotech, Corp., a clinical-stage biotechnology […]
